أطروحة الماجستير للطالبة عبير خالد ملكاوي من قسم الصيدلة السريرية

ناقشت بنجاح طالبة الماجستير  عبير خالد ملكاوي من قسم الصيدلة السريرية يوم الأحد الموافق 22/5/2016م أطروحة الماجستير بعنوان:

STUDYING THE IN-VIVO SIDE EFFECTS OF DEXAMETHASONE AT METABOLIC LEVEL

وقد ضمت لجنة المناقشة الأستاذ الدكتور كارم الزعبي رئيساً وعضوية كل من الدكتور فلاح المهنا والدكتور بلال الحسين والدكتور أحمد العزايزة والدكتور أمجد أبو رميلة كممتحن خارجي.

باسم صفحة أصدقاء كلية الصيدلة_ في جامعة العلوم والتكنولوجيا الأردنية نبارك للطالبة عبير ملكاوي إتمامها درجة الماجستير في الصيدلة السريرية بنجاح وتفوق متمنين لها مزيدا من التقدم.

* للإطلاع على ملخص الدراسة:

Dexamethasone (Dex) is a synthetic glucocorticoid and classified as steroid hormones drug. Dex has anti-inflammatory and immunosuppressant effects, and it is used in several conditions such as asthma and severe allergy. Patients receiving Dex, either at a high dose or for a long time, develop several side effects such as hyperglycemia, weight change, and osteoporosis due to its non-selectivity inside the body. Herein we studied the metabolic changes in rats that developed the Dex side effects after treating them with this drug for 14 weeks. Two groups of Sprague-Dawley male rats (10 each) were involved in this study, where the side effects clinically monitored during the experiment period. The Dex-treated animals were suffering from a severe reduction in weight gain, high blood sugar, essential changes in serum lipid, and reduction in total serum alkaline phosphatase (ALP). Osteocalcin (OC) and β- crosslaps (BCL) are the bone formation, and resorption biomarkers, respectively. Serum OC was reduced significantly (P<0.05), while BCL remained unchanged in Dex group after measuring them by ELISA, which suggests a major reduction in bone formation with slight effect on resorption. The bone weight and size, fracture force, Ca and P contents tests are in agreement with the major bone changes in Dex treated rats. A global metabolic profile using tandem mass spectrometry was performed on rat’s sera, where several metabolic changes were observed, explained and connected to Dex side effects. In particular, most of the amino acids were reduced significantly in Dex group (P<0.0001), which explained the high blood sugar through gluconeogenesis pathway and high level of protein catabolism that lead to severe weight loss. In addition, some of these amino acids were found to be associated with bone metabolism and osteoporosis. The significant increase in some acylcarnitines indicated an elevation in serum fatty acids, and degradation in adipose tissue, which supports the reduction in weight gain. The serum hydroxyproline that produced due to collagen breakdown was increased in Dex and introduced a sensitive marker of bone resorption in the earlier stage before even proven by BCL.